Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
The president of the hospital's Wexner Research ... with Elevidys, a gene therapy for Duchenne muscular dystrophy. He is the first patient to receive the therapy since the FDA approved it for ...
This marks another step in Pfizer’s steady ... With the first US commercial patient dosed in December 2023, Roctavian has enjoyed an uncontested space in hemophilia A gene therapy. Its FDA ...
In the beginning of 2024, it was true that the market was tending to look at the policy of the U.S. Federal Reserve ... 2 Source: “FDA Approves First Gene Therapy for Treatment of Certain ...
The FDA has approved the first over-the-counter (OTC) hearing aid software device for use with compatible versions of Apple Inc.’s (NASDAQ:AAPL) AirPods Pro headphones. Known as the Hearing Aid ...
The Food and Drug Administration on Thursday allowed the first ... The FDA approved the software device, “Hearing Aid Feature,” which the agency said could be installed on Apple’s AirPods ...
There’s a new hope for people living with the rare blood disorder hemophilia B. The FDA recently approved a new gene therapy treatment ... of BEQVEZ, a new Pfizer drug. BEQVEZ is a one-time ...
Moderna’s and Pfizer’s vaccines for kids continue to be available under emergency use authorizations for children six months old through age 11. Novavax is still awaiting an FDA decision on ...
The application was granted Priority Review, Breakthrough Therapy, and Fast Track designations. The FDA approval makes Adstiladrin the first gene therapy ... Merck KGaA/Pfizer’s Bavencio ...
Both Pfizer and Moderna’s shots target the KP.2 COVID-19 variant—JN.1 is the parent variant of KP.2. The FDA in June asked vaccine makers to create shots that target the coronavirus’ JN.
Sanofi received FDA approval for a new manufacturing line to expand production of Beyfortus, a preventive therapy for respiratory syncytial virus in infants. Beyfortus is the first long-acting ...